Braided Suture Adsorbed with Cellular Factor Compositions for Sustained Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current wound healing methods lack a controlled and sustained delivery of physiologically relevant growth factors and cytokines to wound sites, which is essential for optimal healing and recovery, as existing sutures do not effectively maintain consistent protein levels or provide simultaneous delivery of multiple wound healing factors.
Innovation Solution
A novel wound healing device featuring a bioerodable or nonabsorbable braided suture adsorbed with cellular factor-containing compositions, such as Amnion-derived Cellular Cytokine Solution (ACCS) or Physiologic Cytine Solution (PCS), which are released over time through diffusion and suture erosion, providing sustained delivery of factors like VEGF, TIMP-1, TIMP-2, PDGF, and TGFβ2 at physiologic concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protein-based therapeutics are administered to patients, then wound healing factors are delivered to the wound site, but the proteins may denature under processing and storage conditions
Solution Approach 1:
The patent uses a suture material as an intermediary carrier to deliver protein-based therapeutics to the wound site. The suture protects the proteins from denaturation during handling and storage, while allowing controlled release at the target site. This mediator approach resolves the contradiction by providing physical protection without complicating the overall preparation process.
Solution Approach 2:
The patent employs controlled-release formulations that change the release parameters of the proteins over time. By controlling the release rate and timing, the proteins remain stable during storage and only become active when needed at the wound site, resolving the stability versus ease of manufacture contradiction.
2Reliability
If protein concentrations are controlled to maintain steady levels, then optimal healing is achieved, but the administration complexity increases
Solution Approach 1:
The patent prepares controlled-release formulations in advance, loading the suture materials with protein-based therapeutics before administration. This preliminary action allows the complex controlled-release mechanism to be pre-established, simplifying the actual administration process while maintaining steady protein levels at the wound site.
Solution Approach 2:
The controlled-release formulations provide continuous delivery of proteins over an extended period, maintaining steady therapeutic levels without requiring repeated administrations. This continuous action approach resolves the contradiction by achieving reliable protein levels through a single, well-designed formulation rather than multiple complex dosing regimens.
3Productivity
If multiple wound healing factors are delivered simultaneously, then healing is optimized, but the formulation complexity increases
Solution Approach 1:
The patent combines multiple wound healing factors into a single controlled-release formulation loaded onto the suture. This merging approach delivers multiple factors simultaneously to the wound site, optimizing healing while containing the complexity within a single integrated formulation rather than requiring multiple separate applications.
Solution Approach 2:
The suture-based delivery system serves multiple functions: it provides mechanical closure, delivers multiple protein-based therapeutics, and controls release kinetics. This multi-functionality resolves the contradiction by achieving optimized healing through a single universal device rather than multiple specialized formulations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables precise and consistent delivery of multiple wound healing factors directly to the wound site, optimizing healing by maintaining physiologic levels and accelerating recovery, while avoiding the challenges of protein denaturation and fluctuating concentrations.
Implementation Method 1
The CFC, including ACCS, or PCS, are then released into the local wound area over time as a result of a combination of the protein factor release by diffusion and/or the erosion of the bioerodable suture
Implementation Method 2
The CFC, including ACCS, or PCS, are then released into the local wound area over time as a result of a combination of the protein factor release by diffusion and/or the erosion of the bioerodable suture
Implementation Method 3
a nonabsorbable or bioerodable braided suture that has absorbed onto it novel cellular factor-containing compositions (referred to herein as CFC)
Data Source
AI summary
The invention is directed to a novel wound healing device. In particular, the invention is directed to a novel wound healing device comprising a suture or knitted mesh that has adsorbed onto it novel cellular factor-containing compositions (referred to herein as CFC), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) or Physiologic Cytokine Solutions (herein referred to as PCS), as well as methods of making and uses thereof.